Genmab — November 2016
-
Jeg har heller aldrig hørt en CEO sætte kursmål på firmaets aktier. Det er kun hørt fra Winkel
-
Solsen, han bruger da bare enhver lejlighed i medierne til at kommunikere dette til aktionærerne: "don't Sell"
-
“We are proud of the rapid development and approval of DARZALEX for use earlier in the treatment pathway, but our work does not stop here,” said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC. “We are only starting to uncover the full potential of this compound, and we remain committed to the continued study of daratumumab to more fully understand its utility for patients with multiple myeloma and other cancer types.”
-
Sector Shift Underway Leaving Biotech Stocks Behind http://seekingalpha.com/instablog/45557-rod-raynovich/4935660-sector-shift-underway-leaving-biotech-stocks-behind
-
Sektorrotation. Ind i aktier der begunstiges af Trumps politik
-
Per Hansen har helt ret. http://play.borsen.dk/klip/583462c81f5e419167e14122
-
"Man regner med at Genmabs knoglemarvsmiddel kommer på markedet i USA om få dage"...... Flot TV 2
-
TV2 Nyhederne har ikke biotek som hovedområde. Jeg syntes alligevel, at de fik lavet et relevant kort indslag på baggrund af en halv times snak her i aften i Holbæk.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind